Mizumatsu S, Matsumoto K, Maeda Y, Tamiya T, Furuta T, Ohmoto T
Dept. of Neurological Surgery, Okayama University Medical School.
Gan To Kagaku Ryoho. 1998 Nov;25(13):2055-60.
In this study, we examined the clinical course and prognosis of 32 patients with malignant glioma (17 patients with anaplastic astrocytoma, 15 patients with glioblastoma) treated with the MIC regimen (radiation, MCNU, carboplatin and IFN-beta) or MICE regimen (radiation, MCNU, carboplatin, etoposide and IFN-beta). Ten patients were treated with the MIC regimen and 22 patients with the MICE regimen. The patients treated with the MIC and MICE regimens exhibited no significant difference in clinical background factors. The response rate was 50.0% among the 8 evaluable patients treated with the MIC regimen, and 40.0% among the 20 evaluable patients treated with the MICE regimen. The first- and second-year survival rates for the MIC regimen were 40.0% and 30.0%, and those for the MICE regimen were 68.2% and 36.4%. The overall first- and second-year survivals were 59.4% and 33.9%, respectively. The 50% survival time was 8.6 months for the MIC regimen, 14.9 months for the MICE regimen, and 13.4 months overall. There was no significant difference in response rate or survival period between the group treated with the MIC regimen and that treated with the MICE regimen. Age, histological grade of malignancy, radicality of surgery and total dose of irradiation did not affect length of survival. The only factors significantly related to length of survival were response to the induction therapy and performance of maintenance therapy. These results did not demonstrate the superiority of either the MIC or MICE regimen to other regimens previously reported for the treatment of glioma. In addition, etoposide was found not to improve the efficacy of this type of combined chemoradiation therapy.
在本研究中，我们检查了32例接受MIC方案（放疗、甲基环己亚硝脲、卡铂和β干扰素）或MICE方案（放疗、甲基环己亚硝脲、卡铂、依托泊苷和β干扰素）治疗的恶性胶质瘤患者（17例间变性星形细胞瘤患者，15例胶质母细胞瘤患者）的临床病程和预后。10例患者接受MIC方案治疗，22例患者接受MICE方案治疗。接受MIC和MICE方案治疗的患者在临床背景因素方面无显著差异。接受MIC方案治疗的8例可评估患者的缓解率为50.0%，接受MICE方案治疗的20例可评估患者的缓解率为40.0%。MIC方案的1年和2年生存率分别为40.0%和30.0%，MICE方案的1年和2年生存率分别为68.2%和36.4%。总体1年和2年生存率分别为59.4%和33.9%。MIC方案的50%生存时间为8.6个月，MICE方案为14.9个月，总体为13.4个月。接受MIC方案治疗的组与接受MICE方案治疗的组在缓解率或生存期方面无显著差异。年龄、组织学恶性程度、手术根治性和照射总剂量均不影响生存期。与生存期显著相关的唯一因素是诱导治疗的反应和维持治疗的实施情况。这些结果并未证明MIC或MICE方案优于先前报道的用于治疗胶质瘤的其他方案。此外，发现依托泊苷并不能提高这种联合放化疗的疗效。
